≪英文≫

ANGPTL2-mediated epigenetic repression of MHC-I in tumor cells accelerates tumor immune evasion.

Kadomatsu T, Hara C, Kurahashi R, Horiguchi H, Morinaga J, Miyata K, Kurano S, Kanemaru H, Fukushima S, Araki K, Baba M, Linehan WM, Kamba T, Oike Y.

Mol Oncol. 2023;17(12):2637-2658.

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.

Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohayama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators.

Int J Urol. 2023;30(9):788-796.

Real-world treatment outcomes of patients with penile cancer in the Kyushu-Okinawa area of Japan in the pre-guideline era.

Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura K, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T.

Jpn J Clin Oncol. 2023;53(9):837-844.

A Case Report of Aggressive Fumarate Hydrase-deficient Renal Cell Carcinoma With Loss of HLA Antigens.

Miura Y, Motoshima T, Anami T, Takemura K, Kinowaki K, Oka S, Urakami S, Kamba T, Komohara Y.

Microbiol Immunol. 2023;67(7):345-354.

Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.

Miura Y, Motoshima T, Anami T, Yano H, Mito R, Pan C, Urakami S, Kinowaki K, Tsukamoto H, Kurahashi R, Murakami Y, Yatsuda J, Fujiwara Y, Kamba T, Komohara Y.

Microbiol Immunol. 2023;67(7):345-354.

Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.

Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M.

Endocr Relat Cancer. 2023;30(7):e230044.

Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.

Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M.

Cancer Immunol Immunother. 2023;72(6):1903-1915.

Ten-year outcomes of whole-pelvic intensity-modulated radiation therapy for prostate cancer with regional lymph node metastasis.

Nakamura K, Norihisa Y, Ikeda I, Inokuchi H, Aizawa R, Kamoto T, Kamba T, Inoue T, Yamasaki T, Akamatsu S, Kobayashi T, Ogawa O, Mizowaki T.

Cancer Med. 2023;12(7):7859-7867.

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma.

Segawa T, Motoshima T, Yatsuda J, Kurahashi R, Fukushima Y, Murakami Y, Yamaguchi T, Sugiyama Y, Yoshida R, Nakayama H, Kamba T.

IJU Case Rep. 2023;6(2):147-149.

The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.

Terada N, Sawada A, Kawanishi H, Fujimoto T, Magaribuchi T, Chihara I, Hashimoto K, Sakurai T, Shimizu Y, Uegaki M, Nakashima M, Narita S, Kubota M, Yamada Y, Tohi Y, Okabe K, Yatsuda J, Kamoto T.

Int J Urol. 2023;30(2):227-234.

Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study.

Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Kimura G, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H.

(Motoshima Takanobu is indicated in List of Investigators, Supplementary Appendix.)

Pathology. 2023;55(1):31-39.

≪和文≫

RARPにおける術前評価を活かしたトラブル予防及び術中リカバリー

矢津田旬二，神波大己

Jpn J Endurol Robot. 2023;36(2):170-174.

下大静脈内への進展を伴った腎血管筋脂肪腫の１例

眞鍋笙之介，村上洋嗣，脊川卓也，倉橋竜磨，元島崇信，矢津田旬二，杉山豊，神波大己

西日泌尿. 2023;86(1):28-32.

画像上腎細胞癌が疑われた後腹膜リンパ脈管筋腫症（LAM）の一例

愛甲泉，倉橋竜磨，脊川卓也，元島崇信，村上洋嗣，矢津田旬二，杉山豊，神波大己

西日泌尿. 2023;85(5):381-385.

前立腺癌肉腫の診断で骨盤内臓全摘術後，再発に対してイホスファミド・ドキソルビシン併用療法を行い病勢安定した１例

尾﨑陽二郎，元島崇信，山中広太郎，倉橋竜磨，福島結美，村上洋嗣，矢津田旬二，山口隆大，杉山豊，西一彦，神波大己

西日泌尿. 2023;85(5):376-380.

腎細胞癌骨転移に伴うAAアミロイドーシスを発症した一例

久高麗鷹，上川彩乃，倉橋竜磨，脊川卓也，元島崇信，村上洋嗣，矢津田旬二，山口隆大，杉山豊，神波大己

西日泌尿. 2023;85(5):366-370.

ロボット支援腹腔鏡下前立腺全摘除術におけるポートサイトヘルニアへの予防的措置の実践

倉橋竜磨,　脊川卓也，元島崇信，村上洋嗣，矢津田旬二，杉山豊，神波大己

Jpn J Endurol Robot. 2023;36(1):146-150.